5.3.3. tissue-based prognostic biomarker testing. comprehensive literature review several panel discussions american society clinical oncology (asco)-eau-american urological association (aua) multi-disciplinary expert panel made recommendations regarding use tissue-based pca biomarkers. recommendations limited five commercially available tests (oncotype dx, prolaris, decipher, decipher portos promark) extensive validation large retrospective studies evidence test results might actually impact clinical decision-taking. selected commercially available tests significantly improved prognostic accuracy clinical multi-variable models identifying men would benefit cspca requiring curative treatment, well guidance patient management rp. studies showed tissue biomarker tests mri findings independently improved detection cspca setting, remains unclear men would benefit tests. decipherÂ® test outcome associated presence intraductal/invasive cribriform carcinoma retains independent value multi-variable analysis. since long-term impact use commercially available tests oncological outcome remains unproven prospective trials largely lacking, panel concluded tests offered routinely subsets patients test result provides clinically actionable information, instance men favourable intermediate-risk pca might opt men unfavourable intermediate-risk pca scheduled rt decide treatment intensification hormone therapy (ht) .